Chemistry:ETX0462
From HandWiki
ETX0462 is an experimental antibiotic drug which acts both as a β-lactamase inhibitor and also has separate antibiotic activity in its own right. It is active against a range of drug-resistant bacteria of concern including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. While ETX0462 is still in pre-clinical research and has not yet reached clinical trials, it was hailed as a significant advance as it represents an example of a completely new structural class of antibiotics, so even if this particular molecule does not get developed for medical use it is likely that related compounds will continue to be developed.[1][2][3]
See also
References
- ↑ "Rational design of a new antibiotic class for drug-resistant infections". Nature 597 (7878): 698–702. September 2021. doi:10.1038/s41586-021-03899-0. PMID 34526714. Bibcode: 2021Natur.597..698D.
- ↑ "Activity of ETX0462 toward Some Burkholderia spp". Antimicrobial Agents and Chemotherapy 67 (1): e0135222. January 2023. doi:10.1128/aac.01352-22. PMID 36507667.
- ↑ "Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research". Angewandte Chemie 64 (10). November 2024. doi:10.1002/anie.202414325. PMID 39611429.
